BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 13, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2009

View Archived Issues

EMD-121974 combined with chemoradiotherapy may improve survival in cancer patients

Read More

Subretinal gene delivery of adeno-viral RPE65 is safe and effective in retinal degeneration patients

Read More

University of Maryland and Mitsubishi Tanabe Pharma claim KAT II inhibitors for AD

Read More

Boehringer Ingelheim discloses cannabinoid CB2 receptor agonists as analgesics

Read More

New Parkinson's disease clinical trial results reported at Movement Disorder Society meeting

Read More

HIV reverse transcriptase inhibitors in early development at Merck & Co.

Read More

Bayer Schering Pharma patents describe novel prostanoid IP receptor agonists

Read More

Novartis discloses CSF-1R inhibitors for the treatment of cancer

Read More

Efficacy and favorable safety of CCX282-B shown in induction of response phase of PROTECT-1 trial

Read More

BioMarin reports results from phase I PEG-PAL in phenylketonuria

Read More

Talecris receives orphan drug designation for human plasmin

Read More

ViroMed completes dosing in phase I trial for VM-202 in cardiovascular disease

Read More

FDA issues 74-day letter with respect to SkyePharma's NDA for asthma drug Flutiform

Read More

CHMP recommends granting of marketing authorization for Orphan Europe's Vedrop

Read More

FDA cleares Morphotek's IND to study MORAb-004 in solid tumors

Read More

Amarin reports results from phase IIa EN-101 trial in myasthenia gravis

Read More

FDA accepts for filing MonoSol's NDA for ondansetron orally dissolving film strip

Read More

Genmab completes recruitment in zalutumumab head and neck cancer study

Read More

GenPhar prepares tetravalent dengue vaccine for phase I clinical trials

Read More

Kamada reports positive proof-of-concept data for inhaled alpha-1 antitrypsin

Read More

NeurogesX provides FDA regulatory update for Qutenza

Read More

Delcath enrolls 75% of subjects in phase III clinical trial of PHP in melanoma

Read More

Istradefylline reduces off time in Parkinson's disease patients with motor complications

Read More

AS-1907417 shows preclinical potential for the treatment of type 2 diabetes

Read More

CIS-565C improves glucose metabolism with fewer CNS side effects in mouse models of obesity

Read More

Bayhill and Genentech sign worldwide license agreement for BHT-3021 in type 1 diabetes

Read More

Collegium submits SPA to FDA for phase III pivotal trial of tamper-resistant opioid COL-003

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 12, 2026.
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing